- Home
- GWRE vs RPRX Comparison
GWRE vs RPRX Comparison
Compare GWRE & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GWRE | RPRX |
|---|---|---|
| Founded | 2001 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.1B | 16.2B |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GWRE | RPRX |
|---|---|---|
| Price | $210.43 | $39.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 3 |
| Target Price | ★ $272.25 | $46.00 |
| AVG Volume (30 Days) | 705.3K | ★ 4.3M |
| Earning Date | 12-03-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 2.21% |
| EPS Growth | ★ 191.31 | N/A |
| EPS | 1.06 | ★ 1.75 |
| Revenue | $1,272,197,000.00 | ★ $2,349,844,000.00 |
| Revenue This Year | $18.42 | $37.13 |
| Revenue Next Year | $15.17 | $1.48 |
| P/E Ratio | $198.50 | ★ $22.68 |
| Revenue Growth | ★ 22.80 | 3.70 |
| 52 Week Low | $165.09 | $24.05 |
| 52 Week High | $272.60 | $41.24 |
Technical Indicators
Market Signals| Indicator | GWRE | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.89 | 57.50 |
| Support Level | $204.08 | $39.24 |
| Resistance Level | $229.85 | $40.50 |
| Average True Range (ATR) | 7.42 | 0.91 |
| MACD | 0.52 | -0.08 |
| Stochastic Oscillator | 25.88 | 76.02 |
Price Performance
Historical ComparisonAbout GWRE Guidewire Software Inc.
Guidewire Software provides cloud-based software solutions for property and casualty insurers. The flagship product, InsuranceSuite is a system of record and comprises ClaimCenter, a claims management system; PolicyCenter, a policy management system including policy definitions, quotas, issuance, maintenance, and renewal; and BillingCenter, for billing management, payment plans, and agent commissions. The company also offers InsuranceNow, a midmarket offering, as well as a variety of other add-on applications and services.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.